TID MP

PATENT
1718-0195P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	QUIBELL, Martin et al.	Conf.:	8544
Appl. No.:	10/015,186	Group:	1614
Filed:	November 16, 2001	Examiner:	Unassigned
For:	CYSTEINE PROTEASE INHIBITORS		

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents
Washington, DC 20231

June 3, 2002

Sir:

Transmitted herewith is a Petition in the above-identified application.

☒ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	0	-	0	=	0	$18	$0.00
INDEPENDENT	0	-	0	=	0	$84	$0.00
☐ FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						$280	$0.00
						TOTAL	$0.00

☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). $0.00 for the extension of time.

☐ No fee is required.

☒ Check(s) in the amount of $130.00 is(are) enclosed.

☒ Other: Transmittal Letter (dated November 16, 2001)
Express Mail Certificate
Express Mail Label

☐ Please charge Deposit Account No. 02-2448 in the amount of $0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/SWG/sbp
1718-0195P

ATTACHMENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on: 7-3-02
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

_____
(Signature)

7-3-02
(Date of Signature)

(Rev. 09/27/01)

RECEIVED
SEP 12 2002
OFFICE OF PETITIONS

#8

BOX MISSING PARTS
PATENT
Attorney Docket No. 1718-195P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: QUIBELL, Martin et al.

SERIAL NO.: 10/015,186 GROUP: Unassigned

FILED: November 16, 2001 EXAMINER: Unassigned

FOR: CYSTEINE PROTEASE INHIBITORS

PARTIAL RESPONSE TO THE NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION AND PETITION FOR INCLUSION INTO THE APPLICATION OF ALLEGEDLY "OMITTED" MATERIAL

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

July 3, 2002

Sir:

The Notice to File Missing Parts of Nonprovisional Application issued May 3, 2002 in connection with the above-identified application indicated that page 49 of the Specification was missing. However, Applicants submit that page 49 was properly submitted with the original application papers, and should be included in the application as originally filed, with a filing date of November 16, 2001.

The following evidence is enclosed to establish that this page 49 was duly included in the application filed with the USPTO.

(1) The transmittal letter indicating that a Specification consisting of one hundred sixty-six (166) pages was filed on November 16, 2001 by Express mail.

(2) The Express Mail Certificate.

(3) The Express Mail label.

(4) A copy of the Specification as filed which included page 49.

Therefore, pursuant to Section I on page 2 of the May 3, 2002 Notice to File Missing Parts, Applicants petition for inclusion of page 49 into the original filed application.

Should this evidence be deemed insufficient, we note that the transmittal letter filed with the original application papers indicated that the application claims priority to PCT International Application No. PCT/GB00/0184 filed on May 18, 2000, which was published in English and which designated the United States and which was incorporated by reference in its entirety. Enclosed is a copy of pages 23 and 24 of this published PCT application. The text that is present in page 49 of the instant application (the allegedly "omitted" page 49) is recited on page 23, line 9 to page 24, line10 of the WO 00/69855 publication. Therefore, if the above evidence is deemed insufficient to establish that page 49 was filed with the original application papers, the Applicants propose to file an Amendment which adds the same text based upon then incorporation by reference of WO 00/69855.

Upon grant of the above petition, Applicants request a refund of the $130.00 petition fee, which is enclosed in accordance with 37 C.F.R. §1.17(h).

If there are any outstanding matters regarding this Petition, please contact the undersigned at (714) 708-8555 in the Southern California area.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By: _____
Leonard R. Svensson
Registration No. 30,330

P.O. Box 747
Falls Church, VA 22040-0747
(714) 708-8555

LRS/SWG

Attachments

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on: 7-3-02
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

_____
(Signature)

7-3-02
(Date of Signature)

RECEIVED
SEP 12 2002
OFFICE OF PETITIONS

1*H*-Pyrrole-3-carboxylic acid [3,4-dimethyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)pentyl]amide,

1*H*-Pyrrole-3-carboxylic acid [1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3,4-dimethylpentyl]amide,

1*H*-Pyrrole-3-carboxylic acid {1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-3,4-dimethylpentyl}amide,

1*H*-Pyrrole-3-carboxylic acid [3,4-dimethyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)pentyl]amide,

1*H*-Pyrrole-3-carboxylic acid [4,5-dimethyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)hexyl]amide,

1*H*-Pyrrole-3-carboxylic acid [4,5-dimethyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)hexyl]amide,

1*H*-Pyrrole-3-carboxylic acid [1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-4,5-dimethylhexyl]amide,

1*H*-Pyrrole-3-carboxylic acid {1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-4,5-dimethylhexyl}amide,

1*H*-Pyrrole-3-carboxylic acid [4,5-dimethyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)hexyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3-methyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)-3-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3-methyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3-methyl-3-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid {1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-3-methyl-3-phenylbutyl}amide,

1*H*-Pyrrole-3-carboxylic acid [3-methyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)-3-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)-4-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-4-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3,3-dimethyl-4-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid {1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-3,3-dimethyl-4-phenylbutyl}amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)-4-phenylbutyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)-5-phenylpentyl]amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-5-phenylpentyl]amide,

1*H*-Pyrrole-3-carboxylic acid [1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3,3-dimethyl-5-phenylpentyl]amide,

1*H*-Pyrrole-3-carboxylic acid {1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-3,3-dimethyl-5-phenylpentyl}amide,

1*H*-Pyrrole-3-carboxylic acid [3,3-dimethyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)-5-phenylpentyl]amide,

N-[3,3-dimethyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)butyl]benzamide,

N-[3,3-dimethyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)butyl]benzamide,

N-[1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-3,3-dimethylbutyl]benzamide,

N-{1S-[2-(2-dimethylaminoethyl)-4-oxo-tetrahydrofuran-3-ylcarbamoyl]-3,3-dimethylbutyl}benzamide,

N-[3,3-dimethyl-1S-(4-oxo-2-pyrrolidin-1-ylmethyl-tetrahydrofuran-3-ylcarbamoyl)butyl]benzamide,

N-[4-methyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)pentyl]benzamide,

N-[4-methyl-1S-(2-ethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)pentyl]benzamide,

N-[1S-(2-carbamoylmethyl-4-oxo-tetrahydrofuran-3-ylcarbamoyl)-4-methylpentyl]benzamide,